The investigators explain that although “cardiovascular disease (CVD) risk factors are prevalent, and CVD is a leading cause of death among [YA] cancer survivors,” there are limited data on the risk for heart failure in this population.

“Further prospective studies are required to balance the potential benefits of anthracycline vs the cardiovascular risks and to develop surveillance models and susceptibility indexes,” the investigators say in JAMA Network Open .

Cardiovascular disease was also not associated with non-screened cancers.

The use of gonadotropin-releasing hormone agonists is associated with an increased risk for cardiovascular disease in men with prostate cancer and type 2 diabetes, indicates a population-based study.

The USPSTF continues to recommend against the use of beta carotene and vitamin E for the primary prevention of cancer or cardiovascular disease in its updated 2022 recommendations, and maintains that the evidence is insufficient to assess the benefit–risk balance for the use of single- or paired-nutrient and multivitamin supplements.

People with cancer receiving immune checkpoint inhibitors have a significantly higher risk for major adverse cardiovascular events than their unexposed counterparts or the general population, indicate real-world findings.

“These findings highlight patients with [breast cancer] as a vulnerable population at higher risk of developing cardiometabolic risk factors compared with the general population without a history of [breast cancer] and support targeted cardiovascular surveillance by specific patient and treatment characteristics to mitigate these risks,” say Marilyn Kwan (Kaiser Permanente Northern California, Oakland, USA) and team in the Journal of Clinical Oncology .

Severe symptomatic gastrointestinal and sleep-related TRAEs were also more common among women receiving immunotherapy, as were objective cardiovascular and hematologic events.

He also shared data on toxicity, which showed “no difference in deaths from cardiovascular disease or leukemia” in the combined analysis of all trials, but Braybrooke stressed the need for longer-term follow-up. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group SABCS 2021; 7–10 December

Slow recruitment and low event rates have led to early termination of the PRONOUNCE trial, which hoped to determine the relative cardiovascular safety of gonadotropin-releasing hormone antagonists and agonists in men with prostate cancer.

Tsao noted that one patient did not receive protocol-specified surgery due to progressive disease with chest wall invasion and one patient experienced a fatal, postoperative cardiovascular event.

The multicenter, phase 3 trial included 262 women with no history of cardiovascular disease who were undergoing primary or postoperative systemic therapy using an anthracycline-based regimen.

Kerry Courneya and colleagues from the University of Alberta in Edmonton, Canada, report that the primary outcome of peak VO 2 – “an established surrogate marker” for cardiovascular disease and related death – was significantly improved with HIIT versus usual care.

The American Heart Association has released a consensus statement on the management of cardiovascular disease in patients receiving hormonal therapies for breast or prostate cancer.

However, post-marketing data regarding their potential cardiovascular toxicities are scant.

Hormonal factors, reduced physical activity, more lethal or aggressive disease behavior, metabolic syndromes, and potential undertreatment in patients with obesity are possible reasons.”

People receiving immune checkpoint inhibitor therapy for lung cancer or malignant melanoma have a significantly increased risk for cardiovascular events, observational study data show.

Paulette Chandler (Harvard Medical School, Boston, Massachusetts, USA) and co-investigators explain that VITAL was set up to investigate the benefits of vitamin D3 (cholecalciferol, 2000 IU/day) and marine omega-3 fatty acid (1 g/day) supplementation in men aged 50 years or older and women aged 55 years or older who were free of cancer and cardiovascular disease at baseline.

For the trial, men with either biochemical or clinical relapse after local primary intervention with curative intent, newly diagnosed hormone-sensitive metastatic disease, or advanced localized disease unlikely to be cured by local primary intervention with curative intent were randomly assigned to receive relugolix (120 mg/day orally; n=622) or the luteinizing hormone-releasing hormone agonist leuprolide (22.5 or 11.25 mg every 3 months by injection; n=308) for 48 weeks.